Insider Trading › HRTX › Insiders
HERON THERAPEUTICS, INC. /DE/
HRTX·Nasdaq·
United States·Insider activity
United States·Insider activity$0.33
-0.04 (-10.35%)
Close · Oct 6, 2026 · Close Prices from Tiingo.com
HRTX
Insider purchases and sales on the price
Nasdaq 100S&P 500
Filings
Default90D1Y5YALL
HRTXS&P 500 (rebased)
Insider BuyInsider SellForm 144 · planned sale
Loading price history…
Daily closes, adjusted for splits and dividends · Close Prices from Tiingo.comHover a marker, every one is a filing · move across the line for the crosshair
No open-market insider purchases or sales of HRTX were filed in the last 180 days. Newest filing Aug 12, 2025 (1 year ago).
Net Insider Buying by Quarter
Shares bought (+) or sold (−) on the open market by HRTX insiders · Form 4 · last two years
No open-market insider buys or sells in the last two years.
On Record
$0Purchases · 180 days
$0Sales · 180 days
105Open-market transactions on record
0Insiders filing · 180 days
Purchases (code P) and sales (code S) of HRTX common stock reported on Form 4, with Form 5 annual catch-ups. Grants, option exercises, gifts and tax withholding are not shown. Dollars are shares × the stated price; a price outside anything the stock traded at that day is withheld (n/c).
Insider Transactions
105 on record · newest trade first
AllPurchasesSalesOfficers & directors
| Insider | Type | Shares | Price | Value | Held after | Traded | Filed | |
|---|---|---|---|---|---|---|---|---|
| Morgan AdamDirector | Purchase | +1.8M | n/c | — | 8.8Mindirect | Aug 8, 2025 | Aug 12, 2025 | Form 4 ↗ |
| Rosen David Efraim10% owner | Purchase | +2.4M | n/c | — | 29.1Mindirect | Aug 8, 2025 | Aug 12, 2025 | Form 4 ↗ |
| Forbes William PEVP, Chief Development Officer | Purchase | +25.0K | $1.09 | $27K | 79.0Kdirect | Nov 17, 2023 | Nov 21, 2023 | Form 4 ↗ |
| Forbes William PEVP, Chief Development Officer | Purchase | +50.0K | $0.94 | $47K | 54.0Kdirect | Nov 16, 2023 | Nov 20, 2023 | Form 4 ↗ |
| Collard Craig AChief Executive Officer · Director | Purchase | +150.0K | $0.92 | $138K | 186.5Kdirect | Nov 16, 2023 | Nov 17, 2023 | Form 4 ↗ |
| Duarte IraEVP, Chief Financial Officer | Purchase | +85.0K | $0.89 | $76K | 85.0Kdirect | Nov 16, 2023 | Nov 17, 2023 | Form 4 ↗ |
| Morgan AdamDirector | Purchase | +2.5M | $1.37 | $3.4M | 7.0Mindirect | Jul 21, 2023 | Jul 25, 2023 | Form 4 ↗ |
| MANHARD KIMBERLYEVP, Drug Development · Director | Sale | −1,504 | $4.76 | $7K | 10.9Kdirect | May 3, 2022 | May 4, 2022 | Form 4 ↗ |
| Christian WaageDirector | Sale | −300 | $9.73 | $3K | 3,200direct | Dec 21, 2021 | Dec 23, 2021 | Form 4 ↗ |
| Johnson Craig ADirector | Sale | −250 | $9.73 | $2K | 2,840direct | Dec 21, 2021 | Dec 23, 2021 | Form 4 ↗ |
| Christian WaageDirector | Sale | −300 | $12.31 | $4K | 3,500direct | Sep 21, 2021 | Sep 23, 2021 | Form 4 ↗ |
| Johnson Craig ADirector | Sale | −250 | $12.30 | $3K | 3,090direct | Sep 21, 2021 | Sep 23, 2021 | Form 4 ↗ |
| Christian WaageDirector | Sale | −300 | $15.20 | $5K | 3,800direct | Jun 21, 2021 | Jun 22, 2021 | Form 4 ↗ |
| Johnson Craig ADirector | Sale | −250 | $15.20 | $4K | 3,340direct | Jun 21, 2021 | Jun 22, 2021 | Form 4 ↗ |
| MANHARD KIMBERLYEVP, Drug Development · Director | Sale | −1,529 | $17.66 | $27K | 1,634direct | May 3, 2021 | May 4, 2021 | Form 4 ↗ |
| Christian WaageDirector | Sale | −300 | $17.51 | $5K | 4,100direct | Apr 15, 2021 | Apr 16, 2021 | Form 4 ↗ |
| Johnson Craig ADirector | Sale | −250 | $17.22 | $4K | 3,590direct | Apr 6, 2021 | Apr 7, 2021 | Form 4 ↗ |
| Szekeres David LeslieEVP, Chief Operating Officer | Sale | −827 | $18.09 | $15K | 0direct | Jan 14, 2021 | Jan 15, 2021 | Form 4 ↗ |
| Szekeres David LeslieEVP, Chief Operating Officer | Sale | −3,571 | $19.66 | $70K | 0direct | Jan 8, 2021 | Jan 8, 2021 | Form 4 ↗ |
| MANHARD KIMBERLYEVP, Drug Development · Director | Sale | −10.0K | $20.00 | $200K | 0direct | Dec 22, 2020 | Dec 23, 2020 | Form 4 ↗ |
| MANHARD KIMBERLYExecutive VP, Drug Development · Director | Sale | −1,158 | $13.97 | $16K | 0direct | May 1, 2020 | May 1, 2020 | Form 4 ↗ |
| MANHARD KIMBERLYExecutive VP, Drug Development · Director | Sale | −24.0K | $26.00 | $624K | 0direct | Nov 29, 2019 | Dec 3, 2019 | Form 4 ↗ |
| TANG KEVIN CDirector | Purchase | +285.7K | $17.50 | $5.0M | 5.8Mindirect | Oct 4, 2019 | Oct 7, 2019 | Form 4 ↗ |
| Quart Barry DChief Executive Officer · Director | Purchase | +4,571 | $17.50 | $80K | 94.7Kdirect | Oct 3, 2019 | Oct 4, 2019 | Form 4 ↗ |
| POYHONEN JOHNEVP, Chief Commercial Officer · Director | Purchase | +5,143 | $17.50 | $90K | 18.1Kdirect | Oct 3, 2019 | Oct 4, 2019 | Form 4 ↗ |
| POYHONEN JOHNDirector | Purchase | +3,000 | $17.55 | $53K | 13.0Kdirect | May 22, 2019 | May 23, 2019 | Form 4 ↗ |
| Christian WaageDirector | Purchase | +1,400 | $18.04 | $25K | 1,400direct | May 15, 2019 | May 16, 2019 | Form 4 ↗ |
| MANHARD KIMBERLYExecutive VP, Drug Development | Sale | −1,109 | $18.86 | $21K | 0direct | May 1, 2019 | May 2, 2019 | Form 4 ↗ |
| MANHARD KIMBERLYExecutive VP, Drug Development | Sale | −494 | $30.62 | $15K | 0direct | Nov 2, 2018 | Nov 2, 2018 | Form 4 ↗ |
| MANHARD KIMBERLYExecutive VP, Drug Development | Sale | −6,000 | $32.07 | $192K | 0direct | Oct 1, 2018 | Oct 2, 2018 | Form 4 ↗ |
| TANG CAPITAL MANAGEMENT LLC10% owner | Sale | −2.7M | $35.75 | $96.3M | 5.8Mindirect | Sep 12, 2018 | Sep 12, 2018 | Form 4 ↗ |
| MANHARD KIMBERLYExecutive VP, Drug Development | Sale | −100 | $38.85 | $4K | 0direct | Jul 2, 2018 | Jul 3, 2018 | Form 4 ↗ |
| MANHARD KIMBERLYExecutive VP, Drug Development | Sale | −5,900 | $37.51 | $221K | 100direct | Jul 2, 2018 | Jul 3, 2018 | Form 4 ↗ |
| HOFFMAN ROBERTCFO & SVP, Finance | Sale | −1,060 | $38.80 | $41K | 1,280direct | Jul 2, 2018 | Jul 3, 2018 | Form 4 ↗ |
| HOFFMAN ROBERTCFO & SVP, Finance | Sale | −28.9K | $38.15 | $1.1M | 2,340direct | Jul 2, 2018 | Jul 3, 2018 | Form 4 ↗ |
| Rosen RobertPresident · Director | Sale | −3,400 | $38.75 | $132K | 2,640direct | Jul 2, 2018 | Jul 3, 2018 | Form 4 ↗ |
| Rosen RobertPresident · Director | Sale | −92.1K | $38.13 | $3.5M | 6,040direct | Jul 2, 2018 | Jul 3, 2018 | Form 4 ↗ |
| Rosen RobertPresident · Director | Sale | −2,112 | $41.39 | $87K | 2,640direct | Jun 29, 2018 | Jul 3, 2018 | Form 4 ↗ |
| Rosen RobertPresident · Director | Sale | −51.7K | $40.17 | $2.1M | 4,752direct | Jun 29, 2018 | Jul 3, 2018 | Form 4 ↗ |
| Rosen RobertPresident · Director | Sale | −75.7K | $39.14 | $3.0M | 56.4Kdirect | Jun 29, 2018 | Jul 3, 2018 | Form 4 ↗ |
| Quart Barry DChief Executive Officer · Director | Sale | −50.0K | $39.05 | $2.0M | 69.6Kdirect | Jun 21, 2018 | Jun 22, 2018 | Form 4 ↗ |
| TANG CAPITAL PARTNERS LP10% owner | Purchase | +192.3K | $26.00 | $5.0M | 8.5Mindirect | Mar 29, 2018 | Apr 2, 2018 | Form 4 ↗ |
| MANHARD KIMBERLYExecutive VP, Drug Development | Sale | −18.0K | $30.00 | $540K | 0direct | Mar 19, 2018 | Mar 19, 2018 | Form 4 ↗ |
| Quart Barry DChief Executive Officer · Director | Sale | −100.0K | $29.75 | $3.0M | 68.0Kdirect | Mar 19, 2018 | Mar 19, 2018 | Form 4 ↗ |
| Quart Barry DChief Executive Officer · Director | Sale | −100.0K | $24.75 | $2.5M | 68.0Kdirect | Mar 14, 2018 | Mar 16, 2018 | Form 4 ↗ |
| MANHARD KIMBERLYExecutive VP, Drug Development | Sale | −7,584 | $20.00 | $152K | 0direct | Jan 10, 2018 | Jan 12, 2018 | Form 4 ↗ |
| MANHARD KIMBERLYExecutive VP, Drug Development | Sale | −21.5K | $15.33 | $330K | 0direct | Apr 24, 2017 | Apr 24, 2017 | Form 4 ↗ |
| POYHONEN JOHNDirector | Purchase | +10.0K | n/c | — | 10.0Kdirect | Jan 19, 2017 | Jan 23, 2017 | Form 4 ↗ |
| TANG CAPITAL PARTNERS LP10% owner | Purchase | +2.5M | n/c | — | 8.3Mindirect | Jan 19, 2017 | Jan 23, 2017 | Form 4 ↗ |
| Rosen RobertPresident & CCO · Director | Sale | −12.4K | $23.89 | $296K | 2,640direct | Aug 10, 2016 | Aug 12, 2016 | Form 4 ↗ |
| Rosen RobertPresident & CCO · Director | Sale | −87.6K | $23.21 | $2.0M | 15.0Kdirect | Aug 10, 2016 | Aug 12, 2016 | Form 4 ↗ |
| Rosen RobertPresident · Director | Sale | −19.7K | $22.15 | $436K | 2,640direct | Apr 21, 2016 | Apr 21, 2016 | Form 4 ↗ |
| Rosen RobertPresident · Director | Sale | −4,010 | $22.19 | $89K | 2,640direct | Apr 20, 2016 | Apr 21, 2016 | Form 4 ↗ |
| Rosen RobertPresident · Director | Sale | −6,230 | $25.11 | $156K | 2,640direct | Apr 19, 2016 | Apr 21, 2016 | Form 4 ↗ |
| Rosen RobertPresident · Director | Sale | −32.2K | $24.49 | $789K | 8,870direct | Apr 19, 2016 | Apr 21, 2016 | Form 4 ↗ |
| Rosen RobertPresident · Director | Sale | −76.9K | $23.47 | $1.8M | 41.1Kdirect | Apr 19, 2016 | Apr 21, 2016 | Form 4 ↗ |
| Rosen RobertPresident · Director | Sale | −60.9K | $22.50 | $1.4M | 118.0Kdirect | Apr 19, 2016 | Apr 21, 2016 | Form 4 ↗ |
| TANG CAPITAL PARTNERS LP10% owner | Purchase | +121.2K | n/c | — | 4.9Mindirect | Jun 10, 2015 | Jun 12, 2015 | Form 4 ↗ |
| MANHARD KIMBERLYDirector | Sale | −10.5K | $23.58 | $248K | 0direct | Jun 2, 2015 | Jun 3, 2015 | Form 4 ↗ |
| TANG KEVIN CDirector · 10% owner | Purchase | +32.4K | $23.84 | $772K | 4.7Mindirect | Jun 2, 2015 | Jun 2, 2015 | Form 4 ↗ |
| MANHARD KIMBERLYDirector | Sale | −2,708 | $21.17 | $57K | 0direct | Jun 1, 2015 | Jun 3, 2015 | Form 4 ↗ |
| TANG KEVIN CDirector · 10% owner | Purchase | +2,380 | $19.30 | $46K | 4.7Mindirect | Jun 1, 2015 | Jun 2, 2015 | Form 4 ↗ |
| TANG KEVIN CDirector · 10% owner | Purchase | +115.2K | $19.74 | $2.3M | 4.7Mindirect | May 29, 2015 | Jun 2, 2015 | Form 4 ↗ |
| Marshall PaulSVP, Technical Operations | Sale | −20.0K | $15.40 | $308K | 0direct | Mar 5, 2015 | Mar 9, 2015 | Form 4 ↗ |
| Marshall PaulSVP, Technical Operations | Sale | −50.0K | $14.40 | $720K | 20.0Kdirect | Mar 5, 2015 | Mar 9, 2015 | Form 4 ↗ |
| Quart Barry DChief Executive Officer · Director | Sale | −10.0K | $13.07 | $131K | 42.9Kdirect | Mar 2, 2015 | Mar 4, 2015 | Form 4 ↗ |
| Savitr Capital, LLC | Sale | −1,000 | $9.80 | $10K | 1.7Mdirect | Dec 23, 2014 | Feb 12, 2015 | Form 4 ↗ |
| Savitr Capital, LLC | Sale | −2,000 | $9.65 | $19K | 1.7Mdirect | Dec 22, 2014 | Feb 12, 2015 | Form 4 ↗ |
| Savitr Capital, LLC | Sale | −1,000 | $9.33 | $9K | 1.7Mdirect | Dec 19, 2014 | Feb 12, 2015 | Form 4 ↗ |
| Midler Andrew R | Sale | −1,000 | $9.33 | $9K | 79.2Kindirect | Dec 19, 2014 | Feb 12, 2015 | Form 4 ↗ |
| Savitr Capital, LLC | Sale | −1,000 | $9.24 | $9K | 1.7Mdirect | Dec 17, 2014 | Feb 12, 2015 | Form 4 ↗ |
| Savitr Capital, LLC | Sale | −3,700 | $9.36 | $35K | 1.7Mdirect | Dec 16, 2014 | Feb 12, 2015 | Form 4 ↗ |
| Savitr Capital, LLC | Sale | −1,000 | $7.42 | $7K | 1.7Mdirect | Oct 24, 2014 | Feb 12, 2015 | Form 4 ↗ |
| Savitr Capital, LLC | Sale | −1,000 | $8.40 | $8K | 1.7Mdirect | Sep 30, 2014 | Feb 12, 2015 | Form 4 ↗ |
| Savitr Capital, LLC | Sale | −3,000 | $8.77 | $26K | 1.7Mdirect | Sep 29, 2014 | Feb 12, 2015 | Form 4 ↗ |
| Midler Andrew R | Sale | −2,000 | $8.74 | $17K | 79.2Kindirect | Sep 29, 2014 | Feb 12, 2015 | Form 4 ↗ |
| Savitr Capital, LLC | Sale | −1,000 | $8.52 | $9K | 1.7Mdirect | Sep 26, 2014 | Feb 12, 2015 | Form 4 ↗ |
| Savitr Capital, LLC | Sale | −1,000 | $8.55 | $9K | 1.7Mdirect | Sep 24, 2014 | Feb 12, 2015 | Form 4 ↗ |
| Savitr Capital, LLC | Sale | −10 | $9.10 | $91 | 1.7Mdirect | Sep 19, 2014 | Feb 12, 2015 | Form 4 ↗ |
| Midler Andrew R | Sale | −1,000 | $9.07 | $9K | 79.2Kindirect | Sep 19, 2014 | Feb 12, 2015 | Form 4 ↗ |
| Savitr Capital, LLC | Sale | −1,000 | $9.28 | $9K | 1.7Mdirect | Jul 31, 2014 | Feb 12, 2015 | Form 4 ↗ |
| Midler Andrew R | Sale | −1,000 | $9.28 | $9K | 79.2Kindirect | Jul 31, 2014 | Feb 12, 2015 | Form 4 ↗ |
| Savitr Capital, LLC | Sale | −3,000 | $9.20 | $28K | 1.7Mdirect | Jul 30, 2014 | Feb 12, 2015 | Form 4 ↗ |
| Midler Andrew R | Sale | −1,000 | $9.32 | $9K | 79.2Kindirect | Jul 30, 2014 | Feb 12, 2015 | Form 4 ↗ |
| Savitr Capital, LLC | Sale | −4,000 | $9.10 | $36K | 1.7Mdirect | Jul 29, 2014 | Feb 12, 2015 | Form 4 ↗ |
| Midler Andrew R | Sale | −1,000 | $9.00 | $9K | 79.2Kindirect | Jul 29, 2014 | Feb 12, 2015 | Form 4 ↗ |
| Savitr Capital, LLC | Sale | −3,000 | $9.03 | $27K | 1.7Mdirect | Jul 25, 2014 | Feb 12, 2015 | Form 4 ↗ |
| Midler Andrew R | Sale | −1,000 | $9.10 | $9K | 79.2Kindirect | Jul 24, 2014 | Feb 12, 2015 | Form 4 ↗ |
| Savitr Capital, LLC | Sale | −3,300 | $12.45 | $41K | 1.7Mdirect | Jul 3, 2014 | Feb 12, 2015 | Form 4 ↗ |
| Midler Andrew R | Sale | −4,000 | $12.55 | $50K | 79.2Kindirect | Jul 2, 2014 | Feb 12, 2015 | Form 4 ↗ |
| TANG CAPITAL MANAGEMENT LLC10% owner | Purchase | +510.6K | $11.75 | $6.0M | 4.6Mindirect | Jun 25, 2014 | Jun 27, 2014 | Form 4 ↗ |
| Quart Barry DChief Executive Officer · Director | Purchase | +10.0K | $11.75 | $118K | 61.9Kdirect | Jun 25, 2014 | Jun 26, 2014 | Form 4 ↗ |
| Savitr Capital, LLC | Sale | −19.1K | $12.82 | $245K | 1.7Mdirect | Jun 24, 2014 | Feb 12, 2015 | Form 4 ↗ |
| Midler Andrew R | Sale | −1,000 | $13.11 | $13K | 79.2Kindirect | Jun 24, 2014 | Feb 12, 2015 | Form 4 ↗ |
| Midler Andrew R | Sale | −1,000 | $12.50 | $13K | 79.2Kindirect | May 7, 2014 | Feb 12, 2015 | Form 4 ↗ |
| Midler Andrew R | Sale | −2,000 | $12.06 | $24K | 79.2Kindirect | Apr 29, 2014 | Feb 12, 2015 | Form 4 ↗ |
| Savitr Capital, LLC | Sale | −1,000 | $14.33 | $14K | 1.7Mdirect | Mar 27, 2014 | Feb 12, 2015 | Form 4 ↗ |
| Savitr Capital, LLC | Sale | −4,000 | $14.10 | $56K | 1.7Mdirect | Mar 25, 2014 | Feb 12, 2015 | Form 4 ↗ |
| Savitr Capital, LLC | Sale | −3,000 | $15.30 | $46K | 1.7Mdirect | Mar 21, 2014 | Feb 12, 2015 | Form 4 ↗ |
| Savitr Capital, LLC | Sale | −5,000 | $15.58 | $78K | 1.7Mdirect | Mar 20, 2014 | Feb 12, 2015 | Form 4 ↗ |
| Savitr Capital, LLC | Sale | −10.0K | $15.53 | $155K | 1.7Mdirect | Mar 19, 2014 | Feb 12, 2015 | Form 4 ↗ |
| Savitr Capital, LLC | Sale | −10.0K | $15.18 | $152K | 1.7Mdirect | Mar 18, 2014 | Feb 12, 2015 | Form 4 ↗ |
| Savitr Capital, LLC | Sale | −2,000 | $14.86 | $30K | 1.7Mdirect | Mar 14, 2014 | Feb 12, 2015 | Form 4 ↗ |
| Savitr Capital, LLC | Sale | −4,000 | $14.57 | $58K | 1.7Mdirect | Mar 13, 2014 | Feb 12, 2015 | Form 4 ↗ |
| Savitr Capital, LLC | Sale | −9,000 | $14.47 | $130K | 1.7Mdirect | Mar 12, 2014 | Feb 12, 2015 | Form 4 ↗ |
Source: SEC EDGAR Form 4 and Form 5 filings, SEC's quarterly bulk dataset through Jun 30, 2026, and KeyVex's half-hourly read of new filings since. Every row links its filing. Amendments are marked. Nothing here is a recommendation. All insider activity, market-wide →